Brief: Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32
11/02/2026 12:46
Feb 11 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES SIGNS DEFINITIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF EL-22 AND EL-32, A MYOSTATIN-ENGINEERED PROBIOTIC FOR MUSCLE PRESERVATION IN ANIMAL HEALTH Source text: ID:nGNX5PCB0T Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Holdings Signs Non-Binding Letter Of Intent To Acquire Majority Stake In US-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, And Semiconductor Markets
Brief: PMGC Holdings Offers $7.8 Million In Common Stock To Streeterville Capital
NASDAQ RESUMED AT 12:33 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:28 PM
NASDAQ RESUMED AT 09:46 AM